Notice of Half Year Results

RNS Number : 7626C

Oncimmune Holdings PLC

25 February 2022

 

25 February 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Half Year Results

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022.

Analyst and investor presentation

Dr Adam M Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a live presentation of the results, via Investor Meet Company, at 15.00 GMT.

· The online presentation will be open to all existing shareholders and potential new investors.

· Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am GMT the day before the meeting or at any time during the live presentation. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

· Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Company will automatically receive an invitation to the presentation.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS Commercial team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit  www.oncimmune.com

 

END

 

 

NORBUGDDXUDDGDS